Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies - Wikidata - wikimedia - TriplyDB

Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies

Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies

http://www.wikidata.org/entity/Q37228059

about

Understanding the "lethal" drivers of tumor-stroma co-evolution: emerging role(s) for hypoxia, oxidative stress and autophagy/mitophagy in the tumor micro-environment Tumor refractoriness to anti-VEGF therapy Compensatory angiogenesis and tumor refractoriness Anti-angiogenesis and metastasis: a tumour and stromal cell alliance Zebrafish bioassay-guided natural product discovery: isolation of angiogenesis inhibitors from East African medicinal plants Synergistic antitumor effects of endostar in combination with oxaliplatin via inhibition of HIF and CXCR4 in the colorectal cell line SW1116 Theranostic Performance of Acoustic Nanodroplet Vaporization-Generated Bubbles in Tumor Intertissue.Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch.Molecular mechanisms of resistance to tumour anti-angiogenic strategies Stroma-derived HGF drives metabolic adaptation of colorectal cancer to angiogenesis inhibitors Investigational agents in development for the treatment of ovarian cancer Effect of pazopanib on tumor microenvironment and liposome delivery A novel prognostic factor for hepatocellular carcinoma: protein disulfide isomerase.Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy.The effect of network biology on drug toxicology.Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy Dietary restriction promotes vessel maturation in a mouse astrocytoma.Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.Tumour growth inhibition and anti-metastatic activity of a mutated furin-resistant Semaphorin 3E isoform.Anticancer agents that counteract tumor glycolysis.Autocrine production of IL-11 mediates tumorigenicity in hypoxic cancer cells.Recently identified biomarkers that promote lymph node metastasis in head and neck squamous cell carcinoma Enhanced angiogenesis, hypoxia and neutrophil recruitment during Myc-induced liver tumorigenesis in zebrafish Perspective: Opportunities in recalcitrant, rare and neglected tumors.Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy.Etoposide-Bevacizumab a new strategy against human melanoma cells expressing stem-like traits.Controlling escape from angiogenesis inhibitors.HIF-1α/GPER signaling mediates the expression of VEGF induced by hypoxia in breast cancer associated fibroblasts (CAFs)Hypoxia-driven immunosuppression: a new reason to use thermal therapy in the treatment of cancer?The autophagic tumor stroma model of cancer or "battery-operated tumor growth": A simple solution to the autophagy paradox.Perspectives on lymphangiogenesis and angiogenesis in cancer.Angiogenesis in neuroendocrine tumors: therapeutic applications.Current status and future prospects for anti-angiogenic therapies in cancer.Resistance to antiangiogenic therapy.Nanodrug delivery in reversing multidrug resistance in cancer cells.Integrin-mediated cell-matrix interaction in physiological and pathological blood vessel formation.Autophagy, a double-edged sword in anti-angiogenesis therapy.Improving cancer therapies by targeting the physical and chemical hallmarks of the tumor microenvironment.Anti-angiogenic Effects of Bumetanide Revealed by DCE-MRI with a Biodegradable Macromolecular Contrast Agent in a Colon Cancer Model

P2860

Q24620228-E74BDDE7-7D12-4BE3-83B0-FAC2179571BA Q26747678-973EC82C-52B4-43EB-8728-DE8DD1B9A358 Q26851916-A8DF2345-FDDC-42AF-AA22-E79FD0152443 Q26862741-0FB12C72-5A27-4A9E-8192-35C207AD6845 Q28477190-19B5BF2B-E736-4D05-88D4-A32410BCEC08 Q28484315-5F67D0F8-3C09-4528-94AB-8F3A9C6D05BB Q30356036-748E1D3D-50F7-44CD-92BF-832DDB70883C Q33410375-D23E6FE2-81EB-4FD1-88D0-E128679E9EB6 Q33718025-3E87C7EC-B107-4EF5-8C24-632D057FB33D Q33888739-1EDB3FCC-95C0-4092-8154-A6CBF28138C6 Q33920800-400B948A-615A-424F-91F6-2FE8E75951E6 Q34018204-017DA8CE-4A68-4B01-9E34-E14E71A1B4EE Q34184578-1B6485C8-0653-4B4B-9FED-82F1AA93784E Q34300621-2D3DC881-F20F-4FE0-8F17-0C91CC08DDE9 Q34363491-FB22FF94-4C10-45BF-AC7C-2151942E802F Q35008766-49C20209-C451-4DA1-B217-A935452F9DBC Q35664431-9188D14A-3535-4FB0-8288-551DC5F10FFE Q35913662-2300A3C1-7732-4CB6-80D0-C7A6313E82F4 Q35966757-98F34D47-D1E3-489C-A107-6C4906C53E8E Q36037975-7C6D8A03-1537-4F36-A5F5-C75D1DE55155 Q36452381-9C0087BD-CDA1-455C-A136-1E1F4971B35E Q36733388-DA27CA21-99A2-406F-912C-45BEF8F2A028 Q37129819-731871FB-659A-4D24-8FB2-AA5BECACAEB5 Q37195560-484F241A-5606-4FCA-8AE0-17D93BA44357 Q37197528-A57E935B-1A5A-4ED0-AE49-B1E52DBDCB19 Q37578166-F0B90C98-7C48-406A-BD43-591A0EAAC587 Q37588253-EA8CD3BD-426D-4317-ACAA-C19DB0EB1255 Q37672654-12BD948D-159B-42EB-A970-ADA01E1DE0BA Q37690722-7D1A2672-9004-4E72-8A96-DCCB9DE4FD10 Q37730085-64CD25B3-E9E0-4EEC-9717-F7430148FC9F Q37807243-0316721D-1988-4575-B143-AC496A75C3A2 Q37863614-7B2FFD24-2729-4330-9B35-5B9913DE4B4F Q38005887-3C17B236-8188-44DF-A57C-C9A28BAABAB2 Q38088366-ECAEED2B-8AA5-4FC7-8A5C-FD8BC8CF7050 Q38197943-F73FB535-3D3B-4BC9-BCA7-8B5EB23DBA34 Q38234908-7A3D2C6C-57E2-4995-9201-DC8513CCB94F Q38501776-08F29428-8471-4D0D-B5B0-ABBAB205540F Q38682453-C8C48A1F-C8FB-4361-ACAE-422E91415388 Q38685276-79D395F5-DB31-48E0-A1A1-CEB94A207D5B Q38891146-C092801C-1B91-49D9-B4FD-3781B14E6F37

P2860

Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies

http://www.wikidata.org/entity/Q37228059

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 25 April 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies

@en

Role of the hypoxic tumor micr ...... to anti-angiogenic therapies.

@nl

type

label

Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies

@en

Role of the hypoxic tumor micr ...... to anti-angiogenic therapies.

@nl

prefLabel

Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies

@en

Role of the hypoxic tumor micr ...... to anti-angiogenic therapies.

@nl

P1433

Q37228059-16EA8B67-4E95-4924-AED9-F7A255EE4AE2

P1476

Q37228059-35F928C4-34F6-4F41-8A74-9C6F75815D69

P2093

Q37228059-37EFB49D-405E-4745-9EDF-BE8316677B4F

Q37228059-D4C47287-51A1-4091-ABB2-182F4FBCB1B4

P2860

Q37228059-000515B6-5E6B-40E3-A586-F410C60D6EAD

Q37228059-0957CB55-233C-48A0-9CF0-AC16E743A970

Q37228059-0FDF0F26-8193-49B1-A9A3-26B717D9CA8E

Q37228059-12C5DBFE-D3FF-4E5B-AC54-C35680EBFD48

Q37228059-154C88A0-D16F-4DD1-AC49-DD09ACA4529E

Q37228059-1831F302-44B1-479B-ACE2-5617542EF12E

Q37228059-1A6E3933-CB07-4B7A-9996-0ECAB5556793

Q37228059-224E7766-4E82-44BE-905C-46EF6E9050EB

Q37228059-2461D6D2-98F5-4E66-ACDE-F23BD9279035

Q37228059-28C7B667-0D6F-4CDF-A7A6-BD0E0EF00AAF

P304

Q37228059-4B0254AD-3915-43C5-A8FB-3944C20161C4

P31

Q37228059-663EA80A-A5D2-4F16-96BE-82F056B477DC

P356

Q37228059-AF1A79AD-0841-452F-95D4-6952331A8787

P433

Q37228059-A8019A4A-6B7E-47FB-B80E-593DAB8E52B2

P478

Q37228059-820A98F3-8FF5-439F-93F2-8A01EE07A7FF

P577

Q37228059-D7FAA590-286F-4F44-939B-F261B608777B

P5875

Q37228059-41898C2C-3600-4419-92A2-4E1874C85F35

P698

Q37228059-8CFDFB3C-A340-4A60-9628-F3486CA3FB45

P921

Q37228059-EC006DE8-6064-4DCC-B503-099B960E680D

P932

Q37228059-4EA0F5D7-DF0D-4426-9A5E-36F985F3693E

P356

J.DRUP.2009.03.002

P1433

Drug Resistance Updates

P1476

Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies

@en

P2093

Annamaria Rapisarda

http://www.w3.org/2001/XMLSchema#string

Giovanni Melillo

http://www.w3.org/2001/XMLSchema#string

P2860

Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels

Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension

Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche

Modes of resistance to anti-angiogenic therapy

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis

CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma

Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects

P304

74-80

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.DRUP.2009.03.002

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2009-04-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24360585

http://www.w3.org/2001/XMLSchema#string

P698

19394890

http://www.w3.org/2001/XMLSchema#string

P921

P932

2696589

http://www.w3.org/2001/XMLSchema#string